Overall MYOV gets a fundamental rating of 2 out of 10. We evaluated MYOV against 525 industry peers in the Biotechnology industry. MYOV has a bad profitability rating. Also its financial health evaluation is rather negative. MYOV is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year MYOV has reported negative net income.
In the past year MYOV has reported a negative cash flow from operations.

1.2 Ratios

MYOV has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MYOV has a better Gross Margin (73.03%) than 84.43% of its industry peers.
The Profit Margin and Operating Margin are not available for MYOV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	73.03%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYOV has more shares outstanding
Compared to 1 year ago, MYOV has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.98, we must say that MYOV is in the distress zone and has some risk of bankruptcy.
MYOV has a worse Altman-Z score (-2.98) than 60.53% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-2.98

ROIC/WACCN/A

WACC7.64%

2.3 Liquidity

A Current Ratio of 1.57 indicates that MYOV should not have too much problems paying its short term obligations.
MYOV has a Current ratio of 1.57. This is amonst the worse of the industry: MYOV underperforms 84.43% of its industry peers.
A Quick Ratio of 1.45 indicates that MYOV should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.45, MYOV is doing worse than 83.96% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.57
Quick Ratio	1.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.67% over the past year.
MYOV shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.46%.

EPS 1Y (TTM)22.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%13.24%

Revenue 1Y (TTM)91.46%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%84.11%

3.2 Future

MYOV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.08% yearly.
MYOV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.18% yearly.

EPS Next Y19.42%

EPS Next 2Y25.59%

EPS Next 3Y20.67%

EPS Next 5Y25.08%

Revenue Next Year81.1%

Revenue Next 2Y53.4%

Revenue Next 3Y43.72%

Revenue Next 5Y45.18%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MYOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYOV. No positive earnings are expected for the next year.